DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
| Revenue (TTM) | $4.82B |
| Gross Profit (TTM) | $2.96B |
| EBITDA | $1.29B |
| Operating Margin | 21.40% |
| Return on Equity | 35.60% |
| Return on Assets | 9.65% |
| Revenue/Share (TTM) | $12.39 |
| Book Value | $7.66 |
| Price-to-Book | 9.57 |
| Price-to-Sales (TTM) | 5.99 |
| EV/Revenue | 5.66 |
| EV/EBITDA | 18.44 |
| Quarterly Earnings Growth (YoY) | 92.20% |
| Quarterly Revenue Growth (YoY) | 15.00% |
| Shares Outstanding | $385.87M |
| Float | $384.56M |
| % Insiders | 0.26% |
| % Institutions | 104.40% |
Volatility is currently expanding
Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DXCM's Q2 results may reflect strong G7 15 Day adoption, broader reimbursement, and expanding CGM demand as investors watch for continued double-digit revenue growth.
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th.
SAN DIEGO--(BUSINESS WIRE)--Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. Participation in the TEMPO pilot will allow Dexcom.
Here is how DexCom (DXCM) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
DexCom's G7 15 Day wins Health Canada authorization, offering longer wear, high accuracy and smart features for adults with diabetes.
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM whi.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DXCM and any ticker you trade — then tracks every position and per-strategy win rate.
